Hepatic Veno-occlusive disease (VOD) in multiple myeloma patient receiving Belantamab Mafodotin

[1]  V. Paradis,et al.  Hepatic venous pressure gradient in sinusoidal obstruction syndrome: diagnostic value and link with histological lesions , 2022, JHEP reports : innovation in hepatology.

[2]  D. Valla,et al.  Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients With Liver Disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases , 2020, Hepatology.

[3]  F. Ravaioli,et al.  Diagnosis and Treatment of VOD/SOS After Allogeneic Hematopoietic Stem Cell Transplantation , 2020, Frontiers in Immunology.

[4]  Delong Liu,et al.  Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma , 2019, Journal of Hematology & Oncology.

[5]  Z. An,et al.  Antibody-drug conjugates: recent advances in conjugation and linker chemistries , 2016, Protein & Cell.

[6]  M. Abecassis,et al.  Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation , 2016, Bone Marrow Transplantation.

[7]  Heather Donaghy,et al.  Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates , 2016, mAbs.

[8]  Shaji K. Kumar,et al.  Multiple Myeloma: Diagnosis and Treatment. , 2005, Mayo Clinic proceedings.

[9]  M. Abecassis,et al.  Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives—a position statement from the European Society for Blood and Marrow Transplantation (EBMT) , 2015, Bone Marrow Transplantation.